Cargando…
Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer
BACKGROUND AND PURPOSE: We investigated the incidence and dose-volume relationships of radiation pneumonitis (RP) after concurrent chemoradiotherapy (CCRT) followed by durvalumab for locally advanced non-small-cell lung cancer (LA-NSCLC). MATERIALS AND METHODS: We retrospectively analyzed records of...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283100/ https://www.ncbi.nlm.nih.gov/pubmed/32529055 http://dx.doi.org/10.1016/j.ctro.2020.05.006 |
_version_ | 1783544228541890560 |
---|---|
author | Saito, Satoshi Abe, Takanori Kobayashi, Nao Aoshika, Tomomi Ryuno, Yasuhiro Igari, Mitsunobu Hirai, Ryuta Kumazaki, Yu Miura, Yu Kaira, Kyoichi Kagamu, Hiroshi Noda, Shin-ei Kato, Shingo |
author_facet | Saito, Satoshi Abe, Takanori Kobayashi, Nao Aoshika, Tomomi Ryuno, Yasuhiro Igari, Mitsunobu Hirai, Ryuta Kumazaki, Yu Miura, Yu Kaira, Kyoichi Kagamu, Hiroshi Noda, Shin-ei Kato, Shingo |
author_sort | Saito, Satoshi |
collection | PubMed |
description | BACKGROUND AND PURPOSE: We investigated the incidence and dose-volume relationships of radiation pneumonitis (RP) after concurrent chemoradiotherapy (CCRT) followed by durvalumab for locally advanced non-small-cell lung cancer (LA-NSCLC). MATERIALS AND METHODS: We retrospectively analyzed records of 36 patients with LA-NSCLC who underwent CCRT followed by durvalumab. Incidence of RP was analyzed for correlations with clinical factors and dose-volume parameters of lung in radiotherapy. RESULTS: All patients received 60 Gy in 30 fractions of radiotherapy with concurrent chemotherapy. Over a median follow-up period of 7 months, incidence of grade ≥2 RP was 36% (including grade 3 RP: 5% and grade 5 RP: 3%). Age, sex, Brinkman index, and blood test results did not significantly differ between patients with grade ≥2 RP and grade ≤1 RP. Dose-volume parameters (lung volumes that received 5 Gy, 10 Gy, 20 Gy, 30 Gy, 40 Gy, 50 Gy, and mean lung dose) were significantly higher among patients with grade ≥2 RP compared with patients with grade ≤1 RP. CONCLUSION: Incidence of grade ≥2 RP was 36% after CCRT followed by durvalumab for LA-NSCLC, but did not significantly differ from those of patients treated with CCRT alone. Lung dose-volume parameters were significantly correlated with RP. |
format | Online Article Text |
id | pubmed-7283100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-72831002020-06-10 Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer Saito, Satoshi Abe, Takanori Kobayashi, Nao Aoshika, Tomomi Ryuno, Yasuhiro Igari, Mitsunobu Hirai, Ryuta Kumazaki, Yu Miura, Yu Kaira, Kyoichi Kagamu, Hiroshi Noda, Shin-ei Kato, Shingo Clin Transl Radiat Oncol Article BACKGROUND AND PURPOSE: We investigated the incidence and dose-volume relationships of radiation pneumonitis (RP) after concurrent chemoradiotherapy (CCRT) followed by durvalumab for locally advanced non-small-cell lung cancer (LA-NSCLC). MATERIALS AND METHODS: We retrospectively analyzed records of 36 patients with LA-NSCLC who underwent CCRT followed by durvalumab. Incidence of RP was analyzed for correlations with clinical factors and dose-volume parameters of lung in radiotherapy. RESULTS: All patients received 60 Gy in 30 fractions of radiotherapy with concurrent chemotherapy. Over a median follow-up period of 7 months, incidence of grade ≥2 RP was 36% (including grade 3 RP: 5% and grade 5 RP: 3%). Age, sex, Brinkman index, and blood test results did not significantly differ between patients with grade ≥2 RP and grade ≤1 RP. Dose-volume parameters (lung volumes that received 5 Gy, 10 Gy, 20 Gy, 30 Gy, 40 Gy, 50 Gy, and mean lung dose) were significantly higher among patients with grade ≥2 RP compared with patients with grade ≤1 RP. CONCLUSION: Incidence of grade ≥2 RP was 36% after CCRT followed by durvalumab for LA-NSCLC, but did not significantly differ from those of patients treated with CCRT alone. Lung dose-volume parameters were significantly correlated with RP. Elsevier 2020-05-30 /pmc/articles/PMC7283100/ /pubmed/32529055 http://dx.doi.org/10.1016/j.ctro.2020.05.006 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Saito, Satoshi Abe, Takanori Kobayashi, Nao Aoshika, Tomomi Ryuno, Yasuhiro Igari, Mitsunobu Hirai, Ryuta Kumazaki, Yu Miura, Yu Kaira, Kyoichi Kagamu, Hiroshi Noda, Shin-ei Kato, Shingo Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer |
title | Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer |
title_full | Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer |
title_fullStr | Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer |
title_full_unstemmed | Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer |
title_short | Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer |
title_sort | incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283100/ https://www.ncbi.nlm.nih.gov/pubmed/32529055 http://dx.doi.org/10.1016/j.ctro.2020.05.006 |
work_keys_str_mv | AT saitosatoshi incidenceanddosevolumerelationshipofradiationpneumonitisafterconcurrentchemoradiotherapyfollowedbydurvalumabforlocallyadvancednonsmallcelllungcancer AT abetakanori incidenceanddosevolumerelationshipofradiationpneumonitisafterconcurrentchemoradiotherapyfollowedbydurvalumabforlocallyadvancednonsmallcelllungcancer AT kobayashinao incidenceanddosevolumerelationshipofradiationpneumonitisafterconcurrentchemoradiotherapyfollowedbydurvalumabforlocallyadvancednonsmallcelllungcancer AT aoshikatomomi incidenceanddosevolumerelationshipofradiationpneumonitisafterconcurrentchemoradiotherapyfollowedbydurvalumabforlocallyadvancednonsmallcelllungcancer AT ryunoyasuhiro incidenceanddosevolumerelationshipofradiationpneumonitisafterconcurrentchemoradiotherapyfollowedbydurvalumabforlocallyadvancednonsmallcelllungcancer AT igarimitsunobu incidenceanddosevolumerelationshipofradiationpneumonitisafterconcurrentchemoradiotherapyfollowedbydurvalumabforlocallyadvancednonsmallcelllungcancer AT hirairyuta incidenceanddosevolumerelationshipofradiationpneumonitisafterconcurrentchemoradiotherapyfollowedbydurvalumabforlocallyadvancednonsmallcelllungcancer AT kumazakiyu incidenceanddosevolumerelationshipofradiationpneumonitisafterconcurrentchemoradiotherapyfollowedbydurvalumabforlocallyadvancednonsmallcelllungcancer AT miurayu incidenceanddosevolumerelationshipofradiationpneumonitisafterconcurrentchemoradiotherapyfollowedbydurvalumabforlocallyadvancednonsmallcelllungcancer AT kairakyoichi incidenceanddosevolumerelationshipofradiationpneumonitisafterconcurrentchemoradiotherapyfollowedbydurvalumabforlocallyadvancednonsmallcelllungcancer AT kagamuhiroshi incidenceanddosevolumerelationshipofradiationpneumonitisafterconcurrentchemoradiotherapyfollowedbydurvalumabforlocallyadvancednonsmallcelllungcancer AT nodashinei incidenceanddosevolumerelationshipofradiationpneumonitisafterconcurrentchemoradiotherapyfollowedbydurvalumabforlocallyadvancednonsmallcelllungcancer AT katoshingo incidenceanddosevolumerelationshipofradiationpneumonitisafterconcurrentchemoradiotherapyfollowedbydurvalumabforlocallyadvancednonsmallcelllungcancer |